The Top 5 Biosimilar Articles for the Week of August 8

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of August 8, 2022.

Number 5: While efforts to cap monthly insulin costs for Medicare patients at $35 survived a budget reconciliation bill in the Senate, Republicans blocked the measure from extending to the private sector.

Number 4: Coherus Biosciences’ ranibizumab product became the first interchangeable ophthalmology biosimilar to receive FDA approval.

Number 3: Vizient’s Pharmacy Market Outlook report offered predictions on how the emergence of adalimumab biosimilars in 2023 will affect the biosimilar industry and what actions should be taken in advance to ensure biosimilar adoption.

Number 2: In an interview with The Center for Biosimilars®, Hyoung Ki Kim, vice chairman and CEO of Celltrion Healthcare, broke down the benefits of biobetters, how they differ from biosimilars, and how they could alter the future landscape of the biologics industry.

Number 1: FDA has accepted the biologics license application (BLA) for Fresenius Kabi’s biosimilar candidate for tocilizumab (Actemra).

To read all of these articles and more, visit centerforbiosimilars.com.